Indeed, Asunercept (APG101, CAN008), a bivalent fusion protein of the CD95 ectodomain and the Fc domain of human IgG1, is currently under investigation in a clinical phase II trial to treat patients with newly diagnosed glioblastoma (ClinicalTrials.gov Identifier: NCT05447195). Here, FAS is linked to glioblastoma.